GNNSF News and Press, Genscript Biotech Corp From 12/11/22

Summary Chengdu WestGene Biopharma completed a $21 million Series A Round to advance its portfolio of nearly 20 mRNA candidates, including its lead COVID-19 vaccine, which is in IND stage. Suzhou GenAssist Therapeutics raised “millions of dollars” in an A round to support ...

The following slide deck was published by Genscript Biotech Corporation in conjunction with their 2022 Q2 earnings call. For further details see: Genscript Biotech Corporation 2022 Q2 - Results - Earnings Call Presentation

Genscript Biotech press release ( OTCPK:GNNSF ): 1H GAAP EPS of -$0.0628. Revenue of $304.7M (+32.7% Y/Y). For further details see: Genscript Biotech GAAP EPS of -$0.0628, revenue of $304.7M

Genscript Biotech Corporation (GNNSF) Q2 2022 Earnings Conference Call August 31, 2022, 6:00 PM ET Company Participants Shiniu Wei - Chief Financial Officer Robin Meng - Chairman of the Board Patrick Liu - Rotating Chief Executive Officer Ying Huang - Chief E...

GNOM lacks efficient portfolio reshuffling and may not be able to gain from higher alpha-producing stocks in the near future. Despite being a ‘Genomic Revolution’ fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better ‘...

The company expects to lose up to $519 million last year, but its fortunes may improve after its Legend Biotech unit received FDA approval this week for a new CAR-T cell therapy product. Genscript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounti...

The revolutionary technology of synthetic biology is poised to make a profound impact on the way a vast array of products are manufactured, from lab-grown meat to cosmetics to biodegradable packaging. Like the internet revolution, companies that enable or effectively harness synthetic...

Genscript Biotech Corporation (GNNSF): FY gross profit of $260MRevenue of $390M (+42.9% Y/Y) misses by $88.94M.Press Release For further details see: Genscript Biotech Corporation misses on revenue

Genscript Biotech Corporation (GNNSF): FY net loss of ~$281.4MRevenue of $390.8M (+42.9% Y/Y) beats by $44.17M.Press Release For further details see: Genscript Biotech Corporation beats on revenue

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstration Area. Decheng Capital had good reason to be pleased when Merck paid $2.75 billion...